Literature DB >> 1113318

Diagnosis and prognosis in colon cancer based on a profile in immune reactivity.

B B Lurie, D M Bull, N Zamcheck, A M Steward, R A Helms.   

Abstract

An immunologic profile consisting of measurements of circulating carcinoembryonic antigen (CEA), tumor antigen-induced inhibition of monomuclear cell migration (IMM) and skin reactivity to purified protein derivative, streptokinase-streptodornase, and mumps was assessed as a diagnostic and prognostic tool in 16 patients with colon cancer. Preoperatively, 10 of 14 patients tested had elevated CEA, 12 of 12 showed tumor antigen-induced IMM, and 10 of 11 failed to react to 2 or more recall antigens. Potential surgical cure (7 patients) was accompanied by normal CEA in 4, absent tumor antigen-induced IMM in all 7, and increased skin-test reactivity in 6. Disseminated cancer (9 patients) was associated with elevated CEA in all 9, with absent IMM in all 7 and with suppressed skin-test reactivity in 6 of 9.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1113318

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  3 in total

1.  Immunoassessment of patients with gastric cancer. Using leukocyte migration inhibition (LMI) test.

Authors:  O Kojima; Y Uehara; T Majima; E Ikeda; B Nishioka; Y Fujita; S Majima
Journal:  Gastroenterol Jpn       Date:  1983-08

2.  Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival.

Authors:  G Shiota; M Ishida; N Noguchi; K Oyama; Y Takano; M Okubo; S Katayama; Y Tomie; K Harada; K Hori; K Ashida; Y Kishimoto; A Hosoda; T Suou; T Kanbe; K Tanaka; K Nosaka; O Tanida; H Kojo; K Miura; H Ito; N Kaibara; H Kawasaki
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

3.  Change of macrophage migration inhibitory factor: possible indicator for postoperative prognosis.

Authors:  K Orita; T Mannami; M Yumura; S Hayashi; H Miwa
Journal:  Jpn J Surg       Date:  1977-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.